BIODESIX INC — Director's Dealing 2020

Oct 28, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2020-10-27

Reporting Person: Strobeck Matthew (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (16847)		Direct
Series D Preferred Stock	$		Common Stock (115610)		Direct
Series E Preferred Stock	$		Common Stock (126503)		Direct
Series F Preferred Stock	$		Common Stock (152212)		Direct
Series G Preferred Stock	$		Common Stock (279699)		Direct
Series H Preferred Stock	$		Common Stock (140877)		Direct
Series H Preferred Stock	$		Common Stock (21974)		Indirect
Stock Options (Right to Buy)	$6.83	2029-07-15	Common Stock (35158)		Direct
Stock Options (Right to Buy)	$6.83	2030-04-14	Common Stock (35158)		Direct
Stock Options (Right to buy)	$23.74	2022-01-29	Common Stock (3369)		Direct
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (18714)		Indirect
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (76631)		Direct
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (3522)		Indirect
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (3522)		Indirect
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (3522)		Indirect
3% Convertible Debt due June 2021	$	2021-06-30	Common Stock (3522)		Indirect

Footnotes

F1: Every share of Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") is convertible into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") upon the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

F2: The reporting person is an affiliate of Clajer Capital LLC. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: This option vested in 12 successive, equal monthly installments measured from April 1, 2019.

F4: This option vests in 12 successive, equal monthly installments measured from April 1, 2020.

F5: This Convertible Debt pays interest at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt is unpaid, the outstanding principal and unpaid accrued interest shall be automatically converted into Common Stock at the completion of the IPO. The conversion price will be equal to 80% of the price per share paid for the Common Stock sold in the IPO. The conversion price is $14.40, or 80% of the $18 price per share paid for the Common Stock sold in the IPO.

F6: The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.